2X4U - JenaLib

Asymmetric Unit

Reformat:	Number of residues per line = ('0' or empty: single-line sequence representation)
	Number of residues per labelling interval =
	UniProt sequence: complete aligned part

Show mapping:	SCOP domains	CATH domains	Pfam domains	Secondary structure (by author)
	SAPs(SNPs)	PROSITE motifs	Exons
	(details for a mapped element are shown in a popup box when the mouse pointer rests over it)

Chain A from PDB  Type:PROTEIN  Length:275
 aligned with 1A02_HUMAN | P01892 from UniProtKB/Swiss-Prot  Length:365

    Alignment length:275
                                    34        44        54        64        74        84        94       104       114       124       134       144       154       164       174       184       194       204       214       224       234       244       254       264       274       284       294     
           1A02_HUMAN    25 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE 299
               SCOP domains ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- SCOP domains
               CATH domains 2x4uA01 A:1-181 Murine Class I Major Histocompatibility Complex, H2-DB, subunit A, domain 1                                                                                          2x4uA02 A:182-270 Immunoglobulins                                                        ----- CATH domains
               Pfam domains ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Pfam domains
         Sec.struct. author ..eeeeeeeeee........eeeeeeee..eeeeeee........ee.hhhhh..hhhhhhhhhhhhhhhhhhhhhhhhhhhhhh........eeeeeeeeee.....eeeeeeeeee..eeeeee......eee.hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh.....eeeeeeee....eeeeeeeeeee.....eeeeee..ee.hhhhee...ee.....eeeeeeeeee..hhh.eeeeee.......eee... Sec.struct. author
             SAPs(SNPs) (1) --------Y--------------------N----------G-R---------------------GN---Q--ID--------------------L-M-C-------G------------------------------K----------T--E---Q------E--DG--------------------------------------------------------------------E--------------------------------------- SAPs(SNPs) (1)
             SAPs(SNPs) (2) --------------------------------------------------------------------------------------------------F--------------------------------------------------------W----------------------------------------------------------------------------------------------------------------------- SAPs(SNPs) (2)
                    PROSITE ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------IG_MHC ------------ PROSITE
                 Transcript ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Transcript
                 2x4u A   1 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE 275
                                    10        20        30        40        50        60        70        80        90       100       110       120       130       140       150       160       170       180       190       200       210       220       230       240       250       260       270

Chain B from PDB  Type:PROTEIN  Length:100
 aligned with B2MG_HUMAN | P61769 from UniProtKB/Swiss-Prot  Length:119

    Alignment length:100
                                    29        39        49        59        69        79        89        99       109       119
           B2MG_HUMAN    20 AIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM 119
               SCOP domains d2x4ub_ B: beta2-microglobulin                                                                       SCOP domains
               CATH domains 2x4uB00 B:0-99 Immunoglobulins                                                                       CATH domains
               Pfam domains ---------------------------------------------------------------------------------------------------- Pfam domains
         Sec.struct. author ......eeeeee.........eeeeeeeeee.....eeeeee..ee....ee...ee.....eeeeeeeee.......eeeeee.......eeee..... Sec.struct. author
                 SAPs(SNPs) ----------------------------------------------------------------------------N----------------------- SAPs(SNPs)
                    PROSITE ------------------------------------------------------------------------------IG_MHC --------------- PROSITE
                 Transcript ---------------------------------------------------------------------------------------------------- Transcript
                 2x4u B   0 MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM  99
                                     9        19        29        39        49        59        69        79        89        99

Chain C from PDB  Type:PROTEIN  Length:9
 aligned with POL_HV1B1 | P03366 from UniProtKB/Swiss-Prot  Length:1447

    Alignment length:9
            POL_HV1B1   908 ILKEPVHGV 916
               SCOP domains --------- SCOP domains
               CATH domains --------- CATH domains
               Pfam domains --------- Pfam domains
         Sec.struct. author ......... Sec.struct. author
                 SAPs(SNPs) --------- SAPs(SNPs)
                    PROSITE --------- PROSITE
                 Transcript --------- Transcript
                 2x4u C   1 ILKEPVHGV   9

Chain D from PDB  Type:PROTEIN  Length:275
 aligned with 1A02_HUMAN | P01892 from UniProtKB/Swiss-Prot  Length:365

    Alignment length:275
                                    34        44        54        64        74        84        94       104       114       124       134       144       154       164       174       184       194       204       214       224       234       244       254       264       274       284       294     
           1A02_HUMAN    25 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE 299
               SCOP domains ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- SCOP domains
               CATH domains 2x4uD01 D:1-181 Murine Class I Major Histocompatibility Complex, H2-DB, subunit A, domain 1                                                                                          2x4uD02 D:182-270 Immunoglobulins                                                        ----- CATH domains
               Pfam domains ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Pfam domains
         Sec.struct. author ..eeeeeeeeee........eeeeeeee..eeeeeee........ee.hhhhh..hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh.......eeeeeeeeee.....eeeeeeeeee..eeeeee......eee.hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh..........eeeeeeee....eeeeeeeeeee.....eeeeee..ee.hhhhee...ee.....eeeeeeeeee..hhh.eeeeee.......eeee.. Sec.struct. author
             SAPs(SNPs) (1) --------Y--------------------N----------G-R---------------------GN---Q--ID--------------------L-M-C-------G------------------------------K----------T--E---Q------E--DG--------------------------------------------------------------------E--------------------------------------- SAPs(SNPs) (1)
             SAPs(SNPs) (2) --------------------------------------------------------------------------------------------------F--------------------------------------------------------W----------------------------------------------------------------------------------------------------------------------- SAPs(SNPs) (2)
                    PROSITE ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------IG_MHC ------------ PROSITE
                 Transcript ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Transcript
                 2x4u D   1 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE 275
                                    10        20        30        40        50        60        70        80        90       100       110       120       130       140       150       160       170       180       190       200       210       220       230       240       250       260       270

Chain E from PDB  Type:PROTEIN  Length:100
 aligned with B2MG_HUMAN | P61769 from UniProtKB/Swiss-Prot  Length:119

    Alignment length:100
                                    29        39        49        59        69        79        89        99       109       119
           B2MG_HUMAN    20 AIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM 119
               SCOP domains d2x4ue_ E: beta2-microglobulin                                                                       SCOP domains
               CATH domains 2x4uE00 E:0-99 Immunoglobulins                                                                       CATH domains
               Pfam domains ---------------------------------------------------------------------------------------------------- Pfam domains
         Sec.struct. author ......eeeeee.........eeeeeeeeee.....eeeeee..ee....ee...ee.....eeeeeeeee.......eeeeee.......eeee..... Sec.struct. author
                 SAPs(SNPs) ----------------------------------------------------------------------------N----------------------- SAPs(SNPs)
                    PROSITE ------------------------------------------------------------------------------IG_MHC --------------- PROSITE
                 Transcript ---------------------------------------------------------------------------------------------------- Transcript
                 2x4u E   0 MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM  99
                                     9        19        29        39        49        59        69        79        89        99

Chain F from PDB  Type:PROTEIN  Length:9
 aligned with POL_HV1B1 | P03366 from UniProtKB/Swiss-Prot  Length:1447

    Alignment length:9
            POL_HV1B1   908 ILKEPVHGV 916
               SCOP domains --------- SCOP domains
               CATH domains --------- CATH domains
               Pfam domains --------- Pfam domains
         Sec.struct. author ......... Sec.struct. author
                 SAPs(SNPs) --------- SAPs(SNPs)
                    PROSITE --------- PROSITE
                 Transcript --------- Transcript
                 2x4u F   1 ILKEPVHGV   9

Legend:		→ Mismatch	(orange background)
	-	→ Gap	(green background, '-', border residues have a numbering label)
		→ Modified Residue	(blue background, lower-case, 'x' indicates undefined single-letter code, labelled with number + name)
	x	→ Chemical Group	(purple background, 'x', labelled with number + name, e.g. ACE or NH2)
	extra numbering lines below/above indicate numbering irregularities and modified residue names etc., number ends below/above '\|'

Classification and Annotation

SCOP Domains (1, 2)

CATH Domains (2, 6)

Pfam Domains (0, 0)

Gene Ontology (115, 139)

Asymmetric Unit(hide GO term definitions)

Chain A,D (1A02_HUMAN | P01892)

molecular function
	GO:0042608	T cell receptor binding	Interacting selectively and non-covalently with a T cell receptor, the antigen-recognizing receptor on the surface of T cells.
	GO:0046977	TAP binding	Interacting selectively and non-covalently with TAP protein, transporter associated with antigen processing protein. TAP protein is a heterodimeric peptide transporter consisting of the subunits TAP1 and TAP2.
	GO:0030881	beta-2-microglobulin binding	Interacting selectively and non-covalently with beta-2-microglobulin.
	GO:0042605	peptide antigen binding	Interacting selectively and non-covalently with an antigen peptide.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
	GO:0005102	receptor binding	Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
biological process
	GO:0019731	antibacterial humoral response	An immune response against bacteria mediated through a body fluid. Examples of this process are the antibacterial humoral responses in Mus musculus and Drosophila melanogaster.
	GO:0019882	antigen processing and presentation	The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.
	GO:0019885	antigen processing and presentation of endogenous peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex. The peptide antigen is typically, but not always, processed from a whole protein. Class I here refers to classical class I molecules.
	GO:0002486	antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP-independent ER pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class I molecule in the ER following transport from the cytosol via a TAP-independent pathway. Class I here refers to classical class I molecules.
	GO:0002479	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class I molecule. Class I here refers to classical class I molecules.
	GO:0002480	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class I here refers to classical class I molecules.
	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules.
	GO:0050830	defense response to Gram-positive bacterium	Reactions triggered in response to the presence of a Gram-positive bacterium that act to protect the cell or organism.
	GO:0006955	immune response	Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.
	GO:0002376	immune system process	Any process involved in the development or functioning of the immune system, an organismal system for calibrated responses to potential internal or invasive threats.
	GO:0060333	interferon-gamma-mediated signaling pathway	A series of molecular signals initiated by the binding of interferon-gamma to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far.
	GO:2001187	positive regulation of CD8-positive, alpha-beta T cell activation	Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell activation.
	GO:2000566	positive regulation of CD8-positive, alpha-beta T cell proliferation	Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell proliferation.
	GO:0002726	positive regulation of T cell cytokine production	Any process that activates or increases the frequency, rate, or extent of T cell cytokine production.
	GO:0001916	positive regulation of T cell mediated cytotoxicity	Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity.
	GO:0032729	positive regulation of interferon-gamma production	Any process that activates or increases the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.
	GO:2000568	positive regulation of memory T cell activation	Any process that activates or increases the frequency, rate or extent of memory T cell activation.
	GO:0050690	regulation of defense response to virus by virus	Any viral process that modulates the frequency, rate, or extent of the antiviral response of the host cell or organism.
	GO:0050776	regulation of immune response	Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.
	GO:0060337	type I interferon signaling pathway	A series of molecular signals initiated by the binding of a type I interferon to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.
	GO:0016032	viral process	A multi-organism process in which a virus is a participant. The other participant is the host. Includes infection of a host cell, replication of the viral genome, and assembly of progeny virus particles. In some cases the viral genetic material may integrate into the host genome and only subsequently, under particular circumstances, 'complete' its life cycle.
cellular component
	GO:0012507	ER to Golgi transport vesicle membrane	The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi.
	GO:0005794	Golgi apparatus	A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.
	GO:0005797	Golgi medial cisterna	The middle Golgi cisterna (or cisternae).
	GO:0000139	Golgi membrane	The lipid bilayer surrounding any of the compartments of the Golgi apparatus.
	GO:0042612	MHC class I protein complex	A transmembrane protein complex composed of a MHC class I alpha chain and an invariant beta2-microglobin chain, and with or without a bound peptide antigen. Class I here refers to classical class I molecules.
	GO:0009986	cell surface	The external part of the cell wall and/or plasma membrane.
	GO:0031901	early endosome membrane	The lipid bilayer surrounding an early endosome.
	GO:0005783	endoplasmic reticulum	The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).
	GO:0070971	endoplasmic reticulum exit site	An endoplasmic reticulum part at which COPII-coated vesicles are produced.
	GO:0071556	integral component of lumenal side of endoplasmic reticulum membrane	The component of the endoplasmic reticulum membrane consisting of the gene products that penetrate only the lumenal side of the membrane.
	GO:0016021	integral component of membrane	The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
	GO:0016020	membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
	GO:0030670	phagocytic vesicle membrane	The lipid bilayer surrounding a phagocytic vesicle.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Chain B,E (B2MG_HUMAN | P61769)

molecular function
	GO:0042802	identical protein binding	Interacting selectively and non-covalently with an identical protein or proteins.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
biological process
	GO:0033077	T cell differentiation in thymus	The process in which a precursor cell type acquires the specialized features of a T cell via a differentiation pathway dependent upon transit through the thymus.
	GO:0019731	antibacterial humoral response	An immune response against bacteria mediated through a body fluid. Examples of this process are the antibacterial humoral responses in Mus musculus and Drosophila melanogaster.
	GO:0019885	antigen processing and presentation of endogenous peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex. The peptide antigen is typically, but not always, processed from a whole protein. Class I here refers to classical class I molecules.
	GO:0002479	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class I molecule. Class I here refers to classical class I molecules.
	GO:0002480	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class I here refers to classical class I molecules.
	GO:0002481	antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class Ib molecule. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.
	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules.
	GO:0044267	cellular protein metabolic process	The chemical reactions and pathways involving a specific protein, rather than of proteins in general, occurring at the level of an individual cell. Includes cellular protein modification.
	GO:0071281	cellular response to iron ion	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron ion stimulus.
	GO:0071222	cellular response to lipopolysaccharide	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.
	GO:0050829	defense response to Gram-negative bacterium	Reactions triggered in response to the presence of a Gram-negative bacterium that act to protect the cell or organism.
	GO:0050830	defense response to Gram-positive bacterium	Reactions triggered in response to the presence of a Gram-positive bacterium that act to protect the cell or organism.
	GO:0006955	immune response	Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.
	GO:0002376	immune system process	Any process involved in the development or functioning of the immune system, an organismal system for calibrated responses to potential internal or invasive threats.
	GO:0045087	innate immune response	Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.
	GO:0060333	interferon-gamma-mediated signaling pathway	A series of molecular signals initiated by the binding of interferon-gamma to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far.
	GO:0055072	iron ion homeostasis	Any process involved in the maintenance of an internal steady state of iron ions within an organism or cell.
	GO:0010977	negative regulation of neuron projection development	Any process that decreases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).
	GO:1900121	negative regulation of receptor binding	Any process that stops, prevents or reduces the frequency, rate or extent of a protein or other molecule binding to a receptor.
	GO:0002726	positive regulation of T cell cytokine production	Any process that activates or increases the frequency, rate, or extent of T cell cytokine production.
	GO:0001916	positive regulation of T cell mediated cytotoxicity	Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity.
	GO:1904434	positive regulation of ferrous iron binding	Any process that activates or increases the frequency, rate or extent of ferrous iron binding.
	GO:0032092	positive regulation of protein binding	Any process that activates or increases the frequency, rate or extent of protein binding.
	GO:1900122	positive regulation of receptor binding	Any process that activates or increases the frequency, rate or extent of a protein or other molecule binding to a receptor.
	GO:0048260	positive regulation of receptor-mediated endocytosis	Any process that activates or increases the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.
	GO:1904437	positive regulation of transferrin receptor binding	Any process that activates or increases the frequency, rate or extent of transferrin receptor binding.
	GO:0042026	protein refolding	The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.
	GO:0050690	regulation of defense response to virus by virus	Any viral process that modulates the frequency, rate, or extent of the antiviral response of the host cell or organism.
	GO:0050776	regulation of immune response	Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.
	GO:0003254	regulation of membrane depolarization	Any process that modulates the rate, frequency or extent of membrane depolarization. Membrane depolarization is the process in which membrane potential changes in the depolarizing direction from the resting potential, usually from negative to positive.
	GO:0046686	response to cadmium ion	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus.
	GO:0042493	response to drug	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease.
	GO:0002237	response to molecule of bacterial origin	Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of bacterial origin such as peptides derived from bacterial flagellin.
	GO:0001895	retina homeostasis	A tissue homeostatic process involved in the maintenance of an internal equilibrium within the retina of the eye, including control of cellular proliferation and death and control of metabolic function.
cellular component
	GO:0012507	ER to Golgi transport vesicle membrane	The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi.
	GO:0005794	Golgi apparatus	A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.
	GO:0000139	Golgi membrane	The lipid bilayer surrounding any of the compartments of the Golgi apparatus.
	GO:1990712	HFE-transferrin receptor complex	A protein complex containing at least HFE and a transferrin receptor (either TFR1/TFRC or TFR2), proposed to play a role in the sensing of transferrin-bound Fe (Fe2-Tf) on the plasma membrane to regulate hepcidin transcription.
	GO:0042612	MHC class I protein complex	A transmembrane protein complex composed of a MHC class I alpha chain and an invariant beta2-microglobin chain, and with or without a bound peptide antigen. Class I here refers to classical class I molecules.
	GO:0005737	cytoplasm	All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
	GO:0031905	early endosome lumen	The volume enclosed by the membrane of an early endosome.
	GO:0031901	early endosome membrane	The lipid bilayer surrounding an early endosome.
	GO:0005788	endoplasmic reticulum lumen	The volume enclosed by the membranes of the endoplasmic reticulum.
	GO:0009897	external side of plasma membrane	The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface.
	GO:0070062	extracellular exosome	A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm.
	GO:0005576	extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
	GO:0005615	extracellular space	That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.
	GO:0005925	focal adhesion	Small region on the surface of a cell that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments.
	GO:0016020	membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
	GO:0030670	phagocytic vesicle membrane	The lipid bilayer surrounding a phagocytic vesicle.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Chain C,F (POL_HV1B1 | P03366)

molecular function
	GO:0003677	DNA binding	Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid).
	GO:0003887	DNA-directed DNA polymerase activity	Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1); the synthesis of DNA from deoxyribonucleotide triphosphates in the presence of a DNA template and a 3'hydroxyl group.
	GO:0003723	RNA binding	Interacting selectively and non-covalently with an RNA molecule or a portion thereof.
	GO:0004523	RNA-DNA hybrid ribonuclease activity	Catalysis of the endonucleolytic cleavage of RNA in RNA-DNA hybrids to 5'-phosphomonoesters.
	GO:0003964	RNA-directed DNA polymerase activity	Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1). Catalyzes RNA-template-directed extension of the 3'- end of a DNA strand by one deoxynucleotide at a time.
	GO:0004190	aspartic-type endopeptidase activity	Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which a water molecule bound by the side chains of aspartic residues at the active center acts as a nucleophile.
	GO:0003824	catalytic activity	Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic.
	GO:0004519	endonuclease activity	Catalysis of the hydrolysis of ester linkages within nucleic acids by creating internal breaks.
	GO:0004533	exoribonuclease H activity	Catalysis of the exonucleolytic cleavage of RNA to 5'-phosphomonoester oligonucleotides in both 5' to 3' and 3' to 5' directions.
	GO:0016787	hydrolase activity	Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.
	GO:0008289	lipid binding	Interacting selectively and non-covalently with a lipid.
	GO:0046872	metal ion binding	Interacting selectively and non-covalently with any metal ion.
	GO:0004518	nuclease activity	Catalysis of the hydrolysis of ester linkages within nucleic acids.
	GO:0003676	nucleic acid binding	Interacting selectively and non-covalently with any nucleic acid.
	GO:0016779	nucleotidyltransferase activity	Catalysis of the transfer of a nucleotidyl group to a reactant.
	GO:0008233	peptidase activity	Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.
	GO:0005198	structural molecule activity	The action of a molecule that contributes to the structural integrity of a complex or its assembly within or outside a cell.
	GO:0016740	transferase activity	Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.
	GO:0008270	zinc ion binding	Interacting selectively and non-covalently with zinc (Zn) ions.
biological process
	GO:0015074	DNA integration	The process in which a segment of DNA is incorporated into another, usually larger, DNA molecule such as a chromosome.
	GO:0006310	DNA recombination	Any process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents. In eukaryotes genetic recombination can occur by chromosome assortment, intrachromosomal recombination, or nonreciprocal interchromosomal recombination. Intrachromosomal recombination occurs by crossing over. In bacteria it may occur by genetic transformation, conjugation, transduction, or F-duction.
	GO:0090502	RNA phosphodiester bond hydrolysis, endonucleolytic	The chemical reactions and pathways involving the hydrolysis of internal 3',5'-phosphodiester bonds in one or two strands of ribonucleotides.
	GO:0090503	RNA phosphodiester bond hydrolysis, exonucleolytic	The chemical reactions and pathways involving the hydrolysis of terminal 3',5'-phosphodiester bonds in one or two strands of ribonucleotides.
	GO:0006278	RNA-dependent DNA biosynthetic process	A DNA biosynthetic process that uses RNA as a template for RNA-dependent DNA polymerases (e.g. reverse transcriptase) that synthesize the new strand.
	GO:0075713	establishment of integrated proviral latency	A process by which the virus integrates into the host genome and establishes as a stable provirus or prophage.
	GO:0008152	metabolic process	The chemical reactions and pathways, including anabolism and catabolism, by which living organisms transform chemical substances. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation.
	GO:0039526	modulation by virus of host apoptotic process	Any process in which a virus modulates the frequency, rate or extent of apoptosis of infected host cells.
	GO:0090305	nucleic acid phosphodiester bond hydrolysis	The nucleic acid metabolic process in which the phosphodiester bonds between nucleotides are cleaved by hydrolysis.
	GO:0006508	proteolysis	The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.
	GO:0039657	suppression by virus of host gene expression	Any process in which a virus stops, prevents, or reduces the frequency, rate or extent of gene expression in the host organism. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form.
	GO:0046718	viral entry into host cell	The process that occurs after viral attachment by which a virus, or viral nucleic acid, breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the viral nucleic acid is released into the host cell cytoplasm.
	GO:0075732	viral penetration into host nucleus	The crossing by the virus of the host nuclear membrane, either as naked viral genome or for small viruses as an intact capsid.
	GO:0016032	viral process	A multi-organism process in which a virus is a participant. The other participant is the host. Includes infection of a host cell, replication of the viral genome, and assembly of progeny virus particles. In some cases the viral genetic material may integrate into the host genome and only subsequently, under particular circumstances, 'complete' its life cycle.
	GO:0019076	viral release from host cell	The dissemination of mature viral particles from the host cell, e.g. by cell lysis or the budding of virus particles from the cell membrane.
cellular component
	GO:0030430	host cell cytoplasm	The cytoplasm of a host cell.
	GO:0044174	host cell endosome	A membrane-bounded organelle that carries materials newly ingested by endocytosis. It passes many of the materials to host cell lysosomes for degradation.
	GO:0033644	host cell membrane	Double layer of lipid molecules as it encloses host cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins. The host is defined as the larger of the organisms involved in a symbiotic interaction.
	GO:0042025	host cell nucleus	A membrane-bounded organelle as it is found in the host cell in which chromosomes are housed and replicated. The host is defined as the larger of the organisms involved in a symbiotic interaction.
	GO:0020002	host cell plasma membrane	The plasma membrane surrounding a host cell.
	GO:0072494	host multivesicular body	A late endosome in which regions of the limiting host cell endosomal membrane invaginate to form internal vesicles; host membrane proteins that enter the internal vesicles are sequestered from the host cytoplasm.
	GO:0016020	membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
	GO:0019028	viral capsid	The protein coat that surrounds the infective nucleic acid in some virus particles. It comprises numerous regularly arranged subunits, or capsomeres.
	GO:0019013	viral nucleocapsid	The complete protein-nucleic acid complex that is the packaged form of the genome in a virus particle.
	GO:0019012	virion	The complete fully infectious extracellular virus particle.
	GO:0055036	virion membrane	The lipid bilayer surrounding a virion.

Visualization

Interactive Views

Still Images

Databases and Analysis Tools

Databases

Analysis Tools

Related Entries

Entries Sharing at Least One Protein Chain (UniProt ID)

Related Entries Specified in the PDB File

1a1m	MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDETYPDINQML FROM GAG PROTEIN OF HIV2
1a1n	MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTYFROM THE NEF PROTEIN (75- 82) OF HIV1
1a1o	MHC CLASS I MOLECULE B5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM
1a6z	HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
1a9b	DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1a9e	DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1a9m	G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC INHIBITOR U-89360E
1agb	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGRKKYKL - 3R MUTATION)
1agc	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKKYQL - 7Q MUTATION)
1agd	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKKYKL - INDEX PEPTIDE)
1age	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKKYRL - 7R MUTATION)
1agf	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKRYKL - 5R MUTATION)
1ajv	HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC SULFAMIDE INHIBITOR AHA006
1ajx	HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC UREA INHIBITOR AHA001
1akj	COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 ANDTHE T CELL CORECEPTOR CD8
1ao7	COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
1aqd	HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITYPROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED WITH ENDOGENOUSPEPTIDE
1axa	ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT
1b0g	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH BETA 2- MICROGLOBULIN AND HUMAN PEPTIDE P1049
1b0r	CRYSTAL STRUCTURE OF HLA-A0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
1bd2	COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
1bqm	HIV-1 RT/HBY 097
1bqn	TYR 188 LEU HIV-1 RT/HBY 097
1c16	CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/ DELTA T CELL LIGAND T22
1ce6	MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUSNUCLEOPROTEIN PEPTIDE
1cg9	COMPLEX RECOGNITION OF THE SUPERTYPIC BW6- DETERMINANT ONHLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
1d4h	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA435
1d4i	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA425
1d4j	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSL370
1de4	HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRINRECEPTOR
1dlo	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1duy	CRYSTAL STRUCTURE OF HLA-A0201/OCTAMERIC TAX PEPTIDE COMPLEX
1duz	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) INCOMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
1dw6	STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1e27	NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1 (LPPVVAKEI)
1e28	NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2 (TAFTIPSI)
1ebk	STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1ebw	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA322
1eby	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA369
1ebz	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA388
1ec0	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA403
1ec1	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA409
1ec2	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA428
1ec3	HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSA367
1eet	HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH THE INHIBITOR MSC204
1eey	CRYSTAL STRUCTURE DETERMINATION OF HLA A2 COMPLEXED TOPEPTIDE GP2 WITH THE SUBSTITUTION (I2L/V5L/L9V)
1eez	CRYSTAL STRUCTURE DETERMINATION OF HLA-A2.1 COMPLEXED TOGP2 PEPTIDE VARIANT(I2L/V5L)
1efx	STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
1exu	CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
1gzp	CD1B IN COMPLEX WITH GM2 GANGLIOSIDE
1gzq	CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL
1har	HIV-1 REVERSE TRANSCRIPTASE (AMINO-TERMINAL HALF) (FINGERS AND PALM SUBDOMAINS) (RT216)
1hbv	HIV-1 PROTEASE COMPLEXED WITH SB203238
1hef	HIV-1 PROTEASE COMPLEXED WITH SKF 108738 ( HEF)
1heg	HIV-1 PROTEASE COMPLEXED WITH SKF 107457 ( HEG)
1hhg
1hhh
1hhi
1hhj	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM HIV-1 REVERSE TRANSCRIPTASE (RESIDUES 309-317)
1hhk
1hih	HIV-1 PROTEASE COMPLEXED WITH INHIBITOR CGP 53820
1hla	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2 ( HLA-A2, HUMAN LEUCOCYTE ANTIGEN)
1hmv	HIV-1 REVERSE TRANSCRIPTASE
1hni	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE (HIV-1RT) MUTANT WITH CYS 280 REPLACED BY SER (C280S)
1hnv	HIV-1 REVERSE TRANSCRIPTASE (HIV-1 RT) MUTANT WITH CYS 280 REPLACED BY SER (C280S)
1hos	HIV-1 PROTEASE COMPLEX WITH SB204144
1hps	HIV-1 PROTEASE COMPLEXED WITH SB206343
1hpz	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1hqe	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1hqu	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1hrh	RIBONUCLEASE H DOMAIN OF HIV-1 REVERSE TRANSCRIPTASE
1hsa	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA- B(ASTERISK)2705
1hsb	CLASS I HISTOCOMPATIBILITY ANTIGEN AW68.1 ( LEUCOCYTE ANTIGEN)
1hte	HIV-1 PROTEASE COMPLEXED WITH GR123976
1htf	HIV-1 PROTEASE COMPLEXED WITH GR126045
1htg	HIV-1 PROTEASE COMPLEXED WITH GR137615
1hvk	HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR A76928 (S,S)
1hvp	HIV-1 PROTEASE COMPLEX WITH SUBSTRATE ( THEORETICAL MODEL)
1hvu	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE COMPLEXED WITH A 33-BASE NUCLEOTIDE RIBONUCLEIC ACID PSEUDOKNOT
1hys	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEXWITH A POLYPURINE TRACT RNA:DNA
1i1f	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH BETA 2- MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1i1y	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH BETA 2- MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1i4f	CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4- PEPTIDE COMPLEX
1i7r	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1058
1i7t	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-5V
1i7u	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-6V
1ikv	K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITHEFIVARENZ
1ikw	WILD TYPE HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITHEFAVIRENZ
1ikx	K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITHTHE INHIBITOR PNU142721
1iky	HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH THE INHIBITORMSC194
1im3	CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2BOUND TO THE MHC CLASS I MOLECULE HLA-A2/TAX
1im9	CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELLINHIBITORY RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4
1j5o	CRYSTAL STRUCTURE OF MET184ILE MUTANT OF HIV -1 REVERSETRANSCRIPTASE IN COMPLEX WITH DOUBLE STRANDED DNA TEMPLATE-PRIMER
1jf1	CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ADECAMERIC ALTERED PEPTIDE LIGAND FROM THE MART-1/MELAN-A
1jgd	HLA-B*2709 BOUND TO DECA-PEPTIDE S10R
1jge	HLA-B*2705 BOUND TO NONA-PEPTIDE M9
1jht	CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ANONAMERIC ALTERED PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A.
1jnj	NMR SOLUTION STRUCTURE OF THE HUMAN BETA2- MICROGLOBULIN
1k5n	HLA-B*2709 BOUND TO NONA-PEPTIDE M9
1kpr	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEXMOLECULE HLA-E
1ktl	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEXMOLECULE HLA-E
1lds	CRYSTAL STRUCTURE OF MONOMERIC HUMAN BETA-2 -MICROGLOBULIN
1lp9	XENOREACTIVE COMPLEX AHIII 12.2 TCR BOUND TO P1049/HLA-A2.1
1m05	HLA B8 IN COMPLEX WITH AN EPSTEIN BARR VIRUS DETERMINANT
1m6o	CRYSTAL STRUCTURE OF HLA B4402 IN COMPLEX WITH HLADPA0201 PEPTIDE
1mer	HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450
1mes	HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP323
1met	HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323
1meu	HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323
1mhe	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1mi5	THE CRYSTAL STRUCTURE OF LC13 TCR IN COMPLEX WITH HLAB8-EBVPEPTIDE COMPLEX
1n5y	HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO POST-TRANSLOCATION AZTMP-TERMINATED DNA ( COMPLEX P)
1n6q	HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO PRE-TRANSLOCATION AZTMP-TERMINATED DNA ( COMPLEX N)
1npa	CRYSTAL STRUCTURE OF HIV-1 PROTEASE-HUP
1npv	CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LDC271
1npw	CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH LGZ479
1of2	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VPAC1) PEPTIDE (RESIDUES 400-408)
1oga	A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION.
1ogt	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VPAC1) PEPTIDE (RESIDUES 400-408 )
1onq	CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SULFATIDE
1p7q	CRYSTAL STRUCTURE OF HLA-A2 BOUND TO LIR- 1, A HOST ANDVIRAL MHC RECEPTOR
1py4	BETA2 MICROGLOBULIN MUTANT H31Y DISPLAYS HINTS FOR AMYLOIDFORMATIONS
1q94	STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANTNONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THEPRESENCE OF A MIDDLE ANCHOR RESIDUE
1qe1	CRYSTAL STRUCTURE OF 3TC-RESISTANT M184I MUTANT OF HIV-1 REVERSE TRANSCRIPTASE
1qew	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201)COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATEDANTIGEN 3 (RESIDUES 271-279)
1qlf	MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G
1qmc	C-TERMINAL DNA-BINDING DOMAIN OF HIV-1 INTEGRASE, NMR, 42 STRUCTURES
1qqd	CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
1qr1	POOR BINDING OF A HER-2/NEU EPITOPE (GP2 ) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
1qrn	CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
1qse	STRUCTURE OF HUMAN A6-TCR BOUND TO HLA- A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
1qsf	STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
1qvo	STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANTNONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THEPRESENCE OF A MIDDLE ANCHOR RESIDUE
1r0a	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COVALENTLYTETHERED TO DNA TEMPLATE -PRIMER SOLVED TO 2.8 ANGSTROMS
1r3h	CRYSTAL STRUCTURE OF T10
1rdh	HIV-1 REVERSE TRANSCRIPTASE (RIBONUCLEASE H DOMAIN)
1rtd	STRUCTURE OF A CATALYTIC COMPLEX OF HIV-1 REVERSE TRANSCRIPTASE: IMPLICATIONS FOR NUCLEOSIDE ANALOG DRUG RESISTANCE
1rvl	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH ALPHA-APA (R89439) ( THEORETICAL MODEL)
1rvm	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH HEPT (THEORETICAL MODEL)
1rvn	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH PHENYL-ISOINDOLINONE ( THEORETICAL MODEL)
1rvo	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH NEVIRAPINE (THEORETICAL MODEL)
1rvp	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH THIAZOLOISOINDOLINONE ( THEORETICAL MODEL)
1rvq	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH TIBO (THEORETICAL MODEL)
1rvr	REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH IMIDAZODIPYRIDODIAZEPINE (UK -129,485) (THEORETICAL MODEL)
1s6p	CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R100943
1s6q	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH JANSSEN- R147681
1s9e	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH JANSSEN- R129385
1s9g	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH JANSSEN- R120394.
1s9w	CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE, SLLMWITQC,IN COMPLEX WITH HLA-A2
1s9x	CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE,SLLMWITQA, IN COMPLEX WITH HLA-A2
1s9y	CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE,SLLMWITQS, IN COMPLEX WITH HLA-A2
1sbg	HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR SB203386
1suq	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH JANSSEN- R185545
1sv5	CRYSTAL STRUCTURE OF K103N MUTANT HIV-1 REVERSETRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R165335
1sys	CRYSTAL STRUCTURE OF HLA, B*4403, AND PEPTIDE EEPTVIKKY
1syv	HLA-B*4405 COMPLEXED TO THE DOMINANT SELF LIGAND EEFGRAYGF
1t03	HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO TENOFOVIRTERMINATED TEMPLATE-PRIMER (COMPLEX P)
1t05	HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO TEMPLATE-PRIMERWITH TENOFOVIR-DIPHOSPHATE BOUND AS THE INCOMINGNUCLEOTIDE SUBSTRATE
1t7k	CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITHARYLSULFONAMIDE AZACYCLIC UREA
1tmc	TRUNCATED HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA-AW68 COMPLEXED WITH A DECAMERIC PEPTIDE (EVAPPEYHRK)
1tv6	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH CP-94,707
1tvb	CRYSTAL STRUCTURE OF MELANOMA ANTIGEN GP100( 209-217) BOUNDTO HUMAN CLASS I MHC HLA- A2
1tvh	CRYSTAL STRUCTURE OF MODIFIED MELANOMA ANTIGEN GP100(209-T2M) BOUND TO HUMAN CLASS I MHC HLA-A2
1tvr	HIV-1 RT/9-CL TIBO
1uqs	THE CRYSTAL STRUCTURE OF HUMAN CD1B WITH A BOUND BACTERIAL GLYCOLIPID
1ur7	MOLECULAR REFINEMENT OF ANTI-HLA-A2 USING LIGHT CHAIN SHUFFLING: A STRUCTURAL MODEL FOR HLA ANTIBODY BINDING
1uwb	TYR 181 CYS HIV-1 RT/8-CL TIBO
1uxs	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
1uxw	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
1vgk	THE CRYSTAL STRUCTURE OF CLASS I MAJOR HISTOCOMPATIBILITYCOMPLEX, H-2KD AT 2.0 A RESOLUTION
1w0v	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF- RESPONSE FACTOR 1
1w0w	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF- RESPONSE FACTOR 1
1w5v	HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1w5w	HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1w5x	HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1w5y	HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1w72	CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3
1x7q	CRYSTAL STRUCTURE OF HLA-A*1101 WITH SARS NUCLEOCAPSIDPEPTIDE
1xh3	CONFORMATIONAL RESTRAINTS AND FLEXIBILITY OF 14-MERICPEPTIDES IN COMPLEX WITH HLA-B* 3501
1xr8	CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDESFROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1xr9	CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDESFROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1xz0	CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SYNTHETICMYCOBACTIN LIPOPEPTIDE
1ydp	1.9A CRYSTAL STRUCTURE OF HLA-G
1ypz	IMMUNE RECEPTOR
1yt9	HIV PROTEASE WITH OXIMINOARYLSULFONAMIDE BOUND
1zs8	CRYSTAL STRUCTURE OF THE MURINE MHC CLASS IB MOLECULE M10.5
1zsd	CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING AN 11-MER EBVANTIGEN EPLPQGQLTAY
1zt4	THE CRYSTAL STRUCTURE OF HUMAN CD1D WITH AND WITHOUT ALPHA-GALACTOSYLCERAMIDE
2a83	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE GLUCAGONRECEPTOR (GR) PEPTIDE ( RESIDUES 412-420)
2ak4	CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH HLA-B*3508-13MER PEPTIDE
2av1	CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMANCLASS I MHC HLA-A2 WITH THE E63Q AND K66A MUTATIONS IN THEHEAVY CHAIN.
2av7	CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMANCLASS I MHC HLA-A2 WITH THE K66A MUTATION IN THE HEAVYCHAIN.
2axf	THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE ISCONTROLLED BY ITS MHC-BOUND CONFORMATION
2axg	THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE ISCONTROLLED BY ITS MHC-BOUND CONFORMATION
2b5j	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH JANSSEN- R165481
2b6a	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH THR-50
2ban	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH JANSSEN- R157208
2bbb	STRUCTURE OF HIV1 PROTEASE AND HH1_173_3A COMPLEX.
2bck	CRYSTAL STRUCTURE OF HLA-A*2402 COMPLEXED WITH A TELOMERASEPEPTIDE
2be2	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX WITH R221239
2bnq	STRUCTURAL AND KINETIC BASIS FOR HIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2bnr	STRUCTURAL AND KINETIC BASIS FOR HIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2bsr	CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2bss	CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2bst	CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2bvo	STRUCTURES OF THREE HIV-1 HLA-B5703- PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG -TERM NON-PROGRESSION
2bvp	STRUCTURES OF THREE HIV-1 HLA-B5703- PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG -TERM NON-PROGRESSION
2bvq	STRUCTURES OF THREE HIV-1 HLA-B5703- PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG -TERM NON-PROGRESSION
2c7u	CONFLICTING SELECTIVE FORCES AFFECT CD8 T- CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE.
2cii	THE CRYSTAL STRUCTURE OF H-2DB COMPLEXED WITH A PARTIAL PEPTIDE EPITOPE SUGGESTS AN MHC CLASS I ASSEMBLY-INTERMEDIATE
2cik	INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
2clr	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEXED WITH A DECAMERIC PEPTIDE FROM CALRETICULIN
2d31	CRYSTAL STRUCTURE OF DISULFIDE-LINKED HLA-G DIMER
2esv	STRUCTURE OF THE HLA-E-VMAPRTLIL/KK50.4 TCR COMPLEX
2f74	MURINE MHC CLASS I H-2DB IN COMPLEX WITH HUMAN B2-MICROGLOBULIN AND LCMV-DERIVED IMMUNODMINANT PEPTIDE GP33
2f8o	A NATIVE TO AMYLOIDOGENIC TRANSITION REGULATED BY ABACKBONE TRIGGER
2gj6	THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRICACID) PEPTIDE
2h26	HUMAN CD1B IN COMPLEX WITH ENDOGENOUS PHOSPHATIDYLCHOLINEAND SPACER
2hjk	CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2hjl	CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2hla	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN AW 68.1 (HLA-AW 68.1, HUMAN LEUCOCYTE ANTIGEN)
2hmi	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH A DOUBLE-STRANDED DEOXYRIBONUCLEIC ACID AND FAB28
2j8u	LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION.
2jcc	AH3 RECOGNITION OF MUTANT HLA-A2 W167A
2uwe	LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION
2uxz	TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
2uy0	TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
2v2w	T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
2v2x	T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT.
2vb5	SOLUTION STRUCTURE OF W60G MUTANT OF HUMAN BETA2-MICROGLOBULIN
2vg5	CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXES WITH THIOCARBAMATE NON- NUCLEOSIDE INHIBITORS
2vg6	CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXES WITH THIOCARBAMATE NON- NUCLEOSIDE INHIBITORS
2vg7	CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXES WITH THIOCARBAMATE NON- NUCLEOSIDE INHIBITORS
2vlj	THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2vlk	THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2vll	THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2vlr	THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2x4m	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2x4n	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO RESIDUAL FRAGMENTS OF A PHOTOCLEAVABLE PEPTIDE THAT IS CLEAVED UPON UV-LIGHT TREATMENT
2x4o	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO HIV-1 ENVELOPE PEPTIDE ENV120- 128
2x4p	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2x4q	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2x4r	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO CYTOMEGALOVIRUS (CMV) PP65 EPITOPE
2x4s	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO A PEPTIDE REPRESENTING THE EPITOPE OF THE H5N1 (AVIAN FLU) NUCLEOPROTEIN
2x4t	CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2. 1 BOUND TO A PEIODATE-CLEAVABLE PEPTIDE
3hla	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2. 1 (HLA-A2.1 HUMAN LEUCOCYTE ANTIGEN)
3hvt	REVERSE TRANSCRIPTASE
3tlh	STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN EFFICIENT INHIBITOR OF FIV PR

Description

Compounds

Structural Features

Chains, Units

Ligands, Modified Residues, Ions (2, 14)

Sites (14, 14)

SS Bonds (6, 6)

Cis Peptide Bonds (7, 7)

Sequence-Structure Mapping

SAPs(SNPs)/Variants (24, 48)

PROSITE Motifs (1, 4)

Exons (0, 0)

Sequences/Alignments